Nouvelle déclaration d'incident
No de la demande: 2015-3677
Numéro de référence du titulaire d'homologation: PROSAR case #: 1-41439968
Nom du titulaire (nom légal complet, aucune abbréviation): Syngenta Canada Inc.
Adresse: 140 Research Lane, Research Park
Ville: Guelph
État: Ontario
Pays: Canada
Code postal /Zip: N1G4Z3
Incident chez l'humain
Pays: UNITED STATES
État: NORTH CAROLINA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. Inconnu
Nom du produit: Unknown
Liquide
Non
Site: Unknown / Inconnu
Inconnu
Professionnel de la santé
Sexe: Homme
Âge: >19 <=64 yrs / >19 <=64 ans
Système
Unknown / Inconnu
Oui
Oui
Inconnu
Inconnu
Empoisonnement par ingestion d'un produit
Inconnu
Orale
Unknown / Inconnu
Unknown / Inconnu
1-41439968 - The reporter, a doctor, indicated that a patient may have been exposed to an herbicide containing the active ingredient paraquat. The reporter was not able to provide an EPA registration number for the product. He indicated that the name of the product was Three times dead. This name does not match any of the registrant products but the name is not a match for any other companys products either. Per the reporter the patients estranged girlfriend may have added this product to some V8 juice that the patient drank 52 days prior to initial contact with the registrant. The patient also chronically takes methamphetamines. The patient was initially treated at another hospital. Forty-one days after the exposure the patient presented to the callers hospital because of shortness of breath. The patient was diagnosed with community acquired pneumonia. The reporter believes this pneumonia was acquired at another hospital. The patient was put on antibiotics but the patient s symptoms worsened over the next four days and he was finally intubated. The patient was initially on IV fluids but he became hypernatremic so, the fluids were discontinued and he was just being given water through tube feedings. Initial blood work showed an elevation in creatinine (2.9) with a glomerular filtration rate of 23 but at the time of the call creatinine was down to 1.2. The reporter was advised that the delayed onset of the patients symptoms is not consistent with ingestion of the product. On follow-up call, three days later, the reporter indicated that the patient is still being treated for community pneumonia and ARDS and he is doing about the same. The reporter further stated that there was no evidence of pulmonary fibrosis and he did not believe symptoms were due to exposure to paraquat. No additional information is available.
Majeure